FDA Approves CLINDAMYCIN HYDROCHLORIDE — Aurobindo Pharma Limited

Securities and Exchange: Aurobindo Pharma Limited announced the approval of its Abbreviated New Drug Application (ANDA065442) for generic clindamycin hydrochloride tablets, which targets a projected milestone in the oral anti-infective segment and is slated to bolster the company’s product revenue streams following its October 16th launch. Furthermore, this expansion of the generic formulation portfolio is likely to solidify Aurobindo’s competitive positioning in the pharmacy benefit management landscape by capitalizing on the anticipated expiration of brand patents.